drug · small molecule

RHAPSIDO

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for immune system disease and 5 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying RHAPSIDO

phase3A 52-week Study of Remibrutinib in IgE-mediated Food Allergynot yet recruitingn=576
phase2Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticariarecruitingn=44
phase3A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosisrecruitingn=1,275
phase3A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativaactive not recruitingn=565
phase3A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravisrecruitingn=180
phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,000
phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,007
phase3Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.recruitingn=360

more trials →

News(2)

Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.
fiercebiotech · 19d ago
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
biopharma_dive · 27d ago

brand

RHAPSIDO

generic

REMIBRUTINIB

MOA

12.1 Mechanism of Action Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK). BTK is an intracellular protein expressed in mast cells, basophils, B cells, macrophages, and thrombocytes. BTK is involved in intracellular signaling via Fc epsilon receptor-1 (FcεR1), Fc gamma receptors (FcγR), and the B cell antigen receptor (BCR). Remibrutinib also inhibits the BTK-related kinases tec protein tyrosine kinase (TEC) and BMX non-receptor tyrosine kinase (BMX). Remibrutinib inhibits mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.

indication

1 INDICATIONS AND USAGE RHAPSIDO ® is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Limitations of Use: RHAPSIDO is not indicated for other forms of urticaria. RHAPSIDO ® is a kinase inhibitor indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. ( 1 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

RHAPSIDO

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for immune system disease and 5 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying RHAPSIDO

phase3A 52-week Study of Remibrutinib in IgE-mediated Food Allergynot yet recruitingn=576
phase2Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticariarecruitingn=44
phase3A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosisrecruitingn=1,275
phase3A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativaactive not recruitingn=565
phase3A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravisrecruitingn=180
phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,000
phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)active not recruitingn=1,007
phase3Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.recruitingn=360

more trials →

News(2)

Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.
fiercebiotech · 19d ago
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
biopharma_dive · 27d ago

brand

RHAPSIDO

generic

REMIBRUTINIB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

RHAPSIDO

🐶 often sniffed alongside

all catalysts(0)

Trials studying RHAPSIDO

News(2)

Report a data issue

comments(0)

RHAPSIDO

🐶 often sniffed alongside

all catalysts(0)

Trials studying RHAPSIDO

News(2)

Report a data issue

comments(0)